Abstract
We report a case of a 13-year-old girl with chronic recurrent multifocal osteomyelitis (CRMO) who developed severe arthritis in four different joints within the first year from the onset of the disease. Her multiple vertebrae lesions showed significant amelioration after a 2-month treatment with prednisolone. In parallel, the initial severe symmetrical arthritis of both knees showing overt synovitis and joint effusion, in the absence of lesions in the metaphyses of the femur or the tibia, responded remarkably well in intra-articular triamcinolone hexacetonide injections. However, upon discontinuation of prednisolone, the patient developed severe arthritis of her right ankle and the proximal interphalangeal joint of her right middle finger. Thus, prednisolone was reinitiated combined with methotrexate, and the patient went into remission, which persists one year after prednisolone tapering. The appearance of arthritis in both knees in the absence of bone lesions and the emergence of severe arthritis of the ankle after remission of spinal bone lesions suggest that CRMO and juvenile idiopathic arthritis may coexist and be causally related.
Highlights
Chronic recurrent multifocal osteomyelitis (CRMO) or CRMO syndrome (OMIM no. 259680) is a rare inflammatory bone disease presenting usually early in life (∼10 years of age) adults with CRMO have been described
CRMO syndrome is characterized by multiple foci of nonbacterial osteomyelitis appearing radiologically as a mixture of osteolytic/sclerotic lesions
Despite the fact that the human PSTPIP2 gene is encoded within a genomic interval found to be associated with sporadic CRMO by transmission disequilibrium testing [6], no PSTPIP2 mutations have been as yet identified in CRMO syndrome
Summary
The paper titled “Chronic recurrent multifocal osteomyelitis with concomitant features of juvenile idiopathic arthritis” [1], published in Case Reports in Rheumatology, has been retracted as it was submitted for publication without receiving the patient’s consent to be included in the study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.